SNDX Maintained by JP Morgan -- Price Target Lowered to $40.00
JP Morgan has maintained an "Overweight" rating on Syndax Pharmaceuticals (SNDX) but lowered its price target from $44.00 to $40.00. The company, with a market cap of $1.81 billion, faces challenges indicated by its GF Score™ of 22/100 and a high price-to-sales ratio of …